Effect of simultaneous administration of Avemar® and cytostatic drugs on viability of cell cultures, growth of experimental tumors, and survival of tumor-bearing mice

Béla Szende, Zoltán Marcsek, Zsuzsanna Kocsis, Anna Tompa

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Avemar® (Biromedicina Co., Budapest, Hungary), a wheat germ preparation with immunomodulant and antimetastatic activity, was applied simultaneously with cytostatic drugs of different modes of action, in vitro and in vivo, in order to find out whether this simultaneous administration exerts an antagonistic or a synergistic effect on the viability of cell cultures, tumor growth, and survival of animals, inoculated with a transplantable mouse tumor (3LL-HH). In vitro, Avemar did not influence the effect on the viability of MCF-7, HepG2, or Vero cells, exerted by Dacarbazine, 5-fluorouracyl, or Adriblastina. In vivo, Avemar, combined with Endoxan, Navelbine, and doxorubicin, did not prevent the tumor growth inhibitory effect of the cytostatic drugs. The combination of Avemar with the cytostatic drugs did not increase the toxicity of the cytostatic compounds, and did not exert any toxic effect. Avemar may be administered together with cytostatic drugs, without the risk of increasing toxicity or decreasing antiproliferative activity.

Original languageEnglish
Pages (from-to)343-349
Number of pages7
JournalCancer Biotherapy and Radiopharmaceuticals
Volume19
Issue number3
DOIs
Publication statusPublished - Jul 27 2004

Keywords

  • 5-fluorouracyl
  • Adriblastina
  • Avemar®
  • Dacarbazine
  • Endoxan
  • Navelbine

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology
  • Cancer Research

Fingerprint Dive into the research topics of 'Effect of simultaneous administration of Avemar® and cytostatic drugs on viability of cell cultures, growth of experimental tumors, and survival of tumor-bearing mice'. Together they form a unique fingerprint.

  • Cite this